Climb Bio (NASDAQ:CLYM - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02, Zacks reports.
Climb Bio Stock Performance
Shares of NASDAQ:CLYM traded up $0.01 during mid-day trading on Friday, reaching $1.28. 115,261 shares of the company were exchanged, compared to its average volume of 367,710. Climb Bio has a 1 year low of $1.20 and a 1 year high of $11.55. The company has a 50-day moving average price of $1.54. The company has a market cap of $86.37 million, a price-to-earnings ratio of -0.60 and a beta of -0.19.
Wall Street Analysts Forecast Growth
CLYM has been the topic of a number of research analyst reports. Leerink Partnrs upgraded Climb Bio to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners began coverage on shares of Climb Bio in a report on Monday, December 2nd. They issued an "outperform" rating and a $10.00 price objective on the stock.
Check Out Our Latest Analysis on CLYM
About Climb Bio
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Articles
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
